Why Is AGILENT TECHNOLOGIES (A) Stock Up Today?

Agilent Technologies stock is up 3.93% at $138.70 as of the latest trade, driven by the European Union’s approval of the company’s PD-L1 IHC 22C3 pharmDx diagnostic for ovarian and related cancers. The regulatory milestone expands the diagnostic tool’s use in precision oncology, supporting treatment decisions for a broader patient population.

What Happened

The EU approval of Agilent’s PD-L1 IHC 22C3 pharmDx diagnostic allows the test to be used in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may benefit from specific therapies. This follows recent regulatory actions, including FDA approval of the same diagnostic for use with OPDIVO. The approval is part of Agilent’s broader strategy to expand its precision oncology portfolio. The stock opened with a 2.4% gap up from the previous close and reached an intraday high of $141.95 shortly after the market opened.

What The Data Shows

The stock is trading within its 52-week range of $108.35 to $160.27, with a market cap of $37.5 billion and a P/E ratio of 26.8. Intraday volume is at 0.2 million shares, which is 0.1 times the 3-month daily average. Recent insider transactions include a sale by director Mikael Dolsten on May 29, 2026. Congressional trades include a sale by Rep. Ro Khanna on June 30 and a purchase on June 2. Social chatter on X has included analyst updates, including a price target increase by Jefferies to $150 and a reduction by HSBC to $165.

What To Watch

Investors should monitor the company’s upcoming earnings and any further analyst coverage. The next dividend ex-date is scheduled for June 30, 2026.